When the First Treatment Stops Working
Hepatocellular carcinoma (HCC) — the most common form of liver cancer — is one of the harder cancers to treat. Most patients are diagnosed when the disease is already advanced, and while treatments have improved, options narrow quickly once the first drug stops working.
That moment — when the first treatment fails — is where many patients feel they've run out of road.
What Doctors Have Been Up Against
After first-line therapy for advanced HCC fails, second-line treatment options have historically produced modest results. Median survival in these second-line settings has typically hovered in the range of 8 to 10 months.
The GOING trial was designed to test whether a two-drug combination — one targeting tumor blood supply, the other taking the brakes off the immune system — could do better.
Two Drugs, One Strategy
Regorafenib is a drug that blocks signals that tumors use to build new blood vessels. Think of a tumor as a city that needs roads to import supplies. Regorafenib tears up those roads.
Nivolumab is an immunotherapy drug — a PD-1 inhibitor — that removes a molecular "off switch" from immune cells, letting them recognize and attack the tumor more aggressively.
The idea behind combining them is straightforward: cut off the tumor's supply lines while simultaneously unleashing the immune system to go after it.
About the GOING Trial
The Phase I/IIa trial enrolled 67 patients across two groups. Cohort A included patients who had failed sorafenib, a standard first-line drug used for years. Cohort B enrolled patients who had stopped a newer immunotherapy combination (atezolizumab-bevacizumab). Patients started with regorafenib alone for two cycles, then added nivolumab in the third cycle.
The Survival Numbers
The overall median survival across the full group was 20 months — nearly double what second-line liver cancer treatments have historically delivered.
The results in Cohort A were particularly striking. Among patients who progressed on sorafenib, median overall survival reached 25 months. And 45% of those patients were still alive three years after starting the combination.
Cohort B fared more modestly, with a median survival of 8 months — likely reflecting that these patients had already received immunotherapy and may have been less responsive to nivolumab.
That's Not the Full Picture
But here's the catch.
This is an early-phase trial with 67 patients. Without a randomized comparison group, we can't be certain the combination is responsible for the survival improvements — other factors may have influenced outcomes. And severe treatment-related side effects occurred in roughly 28% of patients overall, which is a real consideration.
What Experts Are Watching
Liver cancer specialists note that the 45% three-year survival rate in the sorafenib-failure group is a number that would have seemed impossible a decade ago in second-line HCC. While the trial was not designed to prove a survival benefit definitively, the signal is strong enough that it is being taken seriously.
Researchers suggest that who benefits most may depend on specific tumor biology — and that future trials should use biomarkers to match patients to the right combination.
If you or a family member is dealing with advanced liver cancer and has already tried one line of treatment, this research suggests there may be real options worth discussing with an oncologist. Regorafenib is already approved; nivolumab is approved in certain liver cancer settings. The combination studied here is not yet standard of care, but the data supports asking about clinical trials evaluating it.
This treatment combination is not yet FDA-approved as a standard second-line regimen, and decisions should be made with an oncologist familiar with HCC.
Limitations to Keep in Mind
The GOING trial was small, non-randomized, and conducted at institutions with expertise in complex liver cancer care. Results may not reflect outcomes in broader patient populations or community settings. The patient groups were also analyzed separately given their different treatment histories, making direct comparisons difficult.
The authors call for larger, mechanism-guided randomized trials — ones that select patients based on tumor characteristics to determine who responds best to this combination. If those trials confirm the signal seen here, combination immunotherapy-targeted therapy regimens could become a more formal option in second-line HCC care.
